🏛️ Verified NIH Record • Updated 2026-02-04
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children (NCT05026749)
🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: University of Alabama at Birmingham
🩺 Plain-English Summary (8th-Grade Level)
The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be beneficial, mediated through the matrix metalloproteinase (MMP)-9 pathway.
Who can join: Review the eligibility criteria below.
Location: The University of Alabama at Birmingham — Birmingham, Alabama
Age range: 3 Days to 2 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- The University of Alabama at Birmingham — Birmingham, Alabama
- University of California San Francisco — San Francisco, California
- Yale School of Medicine — New Haven, Connecticut
- Children's National Hospital — Washington D.C., District of Columbia
- Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois
- Riley Children's Health — Indianapolis, Indiana
- St. Louis Children's Hospital — St Louis, Missouri
- University of Nebraska Medical Center — Omaha, Nebraska
- University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
- Rainbow Babies and Children's Hospital — Cleveland, Ohio
- Nationwide Children's Hospital — Columbus, Ohio
- Oklahoma Health Sciences — Oklahoma City, Oklahoma
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- The University of Texas Southwestern Medical Center — Dallas, Texas
- University of Utah — Salt Lake City, Utah
📞 Contact the Study Coordinator
Phone: (205) 638-9387
Email: mkong@uabmc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Respiratory Syncytial Virus Infections
- Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV in Children Under 6 Months in Bogotá — Bogotá,
- Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above — Mobile, Alabama
- An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study — Birmingham, Alabama
- A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant — Lexington, Kentucky
- A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease — Los Angeles, California
- A Study of BLB-201 RSV Vaccine in Infants and Children — La Mesa, California
Explore by condition: All Respiratory Syncytial Virus Infections clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.